New Drug Zorevunersen Cuts Seizures by Up to 91% in Children with Dravet Syndrome in Clinical Trials

For families living with Dravet syndrome, the baseline is relentless. Children with this severe genetic epilepsy can experience dozens of seizures a month — often prolonged, often dangerous — despite being on multiple medications that in other epilepsies would provide adequate control. The existing treatments help some children partially, but meaningful seizure freedom has remained out of reach for most. Clinical trial results for zorevunersen, an experimental antisense oligonucleotide therapy, are now reporting seizure reductions of up to 91% in trial participants. That number needs context and scrutiny, but for a condition where a 50% reduction is considered a major clinical success, 91% represents a result that the epilepsy community is treating with serious attention.

What Dravet Syndrome Actually Is

Dravet syndrome is caused in the vast majority of cases by a mutation in the SCN1A gene, which encodes a sodium channel protein critical for the proper function of inhibitory neurons in the brain. When this channel does not work correctly, the brain's ability to regulate electrical activity breaks down, producing the severe, treatment-resistant seizures that define the condition. The syndrome typically emerges in the first year of life, often triggered initially by fever, and evolves into a lifelong condition associated not just with seizures but with developmental delays, behavioral challenges, sleep disturbances, and significantly elevated mortality risk — including from SUDEP, sudden unexpected death in epilepsy.

Current approved treatments include valproate, clobazam, stiripentol, cannabidiol, and fenfluramine. Each provides benefit for some patients, and combining multiple agents is standard practice. But none of these treatments address the underlying genetic cause. They manage symptoms — reducing seizure frequency and severity — without correcting the SCN1A dysfunction that is driving the condition. For a significant proportion of children with Dravet syndrome, even the best current multi-drug regimen leaves them with frequent, life-disrupting seizures.

How Zorevunersen Works Differently

Zorevunersen is an antisense oligonucleotide — a short synthetic strand of nucleic acid designed to interact with messenger RNA in a specific and targeted way. In the context of SCN1A-related Dravet syndrome, zorevunersen works by targeting a regulatory mechanism that suppresses a functional version of the sodium channel. The SCN1A gene has what is known as a non-productive splice variant — an alternative way the gene's messenger RNA can be processed that produces a non-functional protein. By blocking this non-productive splicing pathway, zorevunersen effectively redirects the cell's machinery toward producing more of the functional sodium channel, partially compensating for the reduced activity caused by the disease-causing mutation.

This approach is meaningfully different from existing Dravet treatments in that it addresses a mechanism downstream of the genetic mutation rather than simply trying to manage the seizure threshold through broad anticonvulsant effects. It does not correct the underlying mutation — zorevunersen is not gene therapy in the traditional sense — but it modulates how the existing genetic information is processed in a way that increases functional sodium channel expression. The result, at least in trial participants, is a brain that is better equipped to maintain inhibitory control over electrical activity.

The Trial Results in Detail

The up-to-91% seizure reduction figure reflects the best responders in the trial cohort — patients at the high end of the response distribution rather than the average across all participants. That distinction matters for setting appropriate expectations. Median seizure reduction across trial participants is the more informative statistic for understanding what a typical patient might experience, and published trial data should be examined for that figure alongside the maximum response. What the trial has demonstrated is that a meaningful proportion of children with Dravet syndrome can achieve dramatic seizure reduction with zorevunersen, and that the range of responses extends to near-complete seizure control in the best cases.

The quality-of-life improvements reported alongside seizure reduction are clinically significant in their own right. For children with Dravet syndrome, frequent severe seizures impose costs beyond the seizures themselves — sleep is disrupted, cognitive development is affected, and the constant monitoring required creates profound family burden. Families reporting meaningful quality-of-life improvements in trial surveys are describing real changes in daily functioning that go beyond what seizure frequency counts alone capture.

What Comes Next on the Path to Approval

Clinical trial results of this magnitude generate a regulatory pathway that both the FDA and EMA prioritize for rare pediatric diseases. Zorevunersen would likely be eligible for breakthrough therapy designation if it has not already received it, which accelerates the review process and provides more intensive FDA guidance during development. The specific trial phase and the size and design of the cohort that produced these results will determine what additional data the agency requires before approval can be granted.

For the Dravet syndrome community — patients, families, neurologists, and advocacy organizations that have been pushing for better treatments for decades — the zorevunersen results are the most significant piece of positive news the field has seen in some time. There is appropriate caution about interpreting early trial results before full regulatory review, but the biological plausibility of the mechanism, the magnitude of the seizure reductions reported, and the quality-of-life improvements combine into a profile that justifies the cautious optimism that neurologists specializing in epilepsy are currently expressing.